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The implementation of novel therapeutic interventions has improved the survival rates of melanoma
patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses.
Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges
that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation,
across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC
isolation and address their potential role in melanoma management.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Although melanoma is potentially curable when detected in its
earliest stages, it can metastasize to other tissues, drastically
reducing survival rates [5]. Recent advances in immune- and targeted therapies have improved survival for metastatic cutaneous
melanoma [35]. However, immunotherapies are highly toxic and
effective in only a proportion of patients [40,48,57], and the majority of patients undergoing targeted therapies with MAPK inhibitors rapidly develop drug resistance [47,49,54]. In order to
overcome these challenges, biomarkers that can guide treatment
decisions, monitor response to treatment and identify resistance,
are urgently required in the clinical setting.
During the last decade, circulating tumor cells (CTCs) have
received widespread attention as prognostic biomarkers [1,18] (see
Table 1 for the full list of terms). These cells are derived from primary and/or metastatic tumors and can be assessed at any point
during disease course. Thus, their presence in peripheral blood can
serve as a ‘‘liquid biopsy’’ of solid tumors, particularly when a biopsy cannot be undertaken due to inaccessibility of the tumor, or
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when multiple metastases are present in a patient. For increased
clinical beneﬁt, the analysis of these tumor-derived cells needs to
assist with (a) disease prognosis, (b) prediction of clinical outcome
to speciﬁc treatment, (c) patient-tailored, real time monitoring of
response, (d) early detection of treatment resistance or recurrence
and progression, and (e) discovery of new therapeutic targets and
mechanisms of resistance. Additionally, the molecular characterization of these rare cells harbors signiﬁcant information about
cancer dissemination.
The enrichment and detection of CTCs from patients is critically
challenging, mainly due to the limited amount of blood sample
available and the very low concentration of these cells in peripheral
blood. For melanoma, the difﬁculties are magniﬁed because common
CTC markers, such as EpCAM, used in CTC enrichment of epithelial
cancers including breast and prostate cancers, are not commonly
expressed by MelCTCs, since melanocytes originate from the neural
crest and not the epithelium [19]. In addition, MelCTCs are a very
heterogeneous population of cells [21,25,29], yet current techniques
used to enrich melanoma cells from blood do not commonly
consider this factor, as their principle for CTC detection relies on the
expression of only one or two markers. The isolation of MelCTCs
usually follows two common steps: ﬁrst, CTCs are enriched from the
background of millions of blood cells and second, CTCs are detected
and characterized in the enriched fraction.

https://doi.org/10.1016/j.canlet.2018.03.013
0304-3835/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
List of terms.
ABCB5
AJCC
BRAF
CD144
CD271
CD34
CD45
CDKN2A
CDX
CNV
CTC
CTM
ddPCR
EpCAM
FDA
gp100
HB-chip
ICC
ISET
KRAS
KRT18
KRT8
MAPK
MCAM
MCSP/CSGP4/HMW-MAA
MDM2
MelCTC
MIF
MITF
MLANA/MART-1
NSG
PAX3
PD-1
PD-L1
PDX
PFS
PTEN
RANK
RBCs
TERT
WBCs

Here we detail the progress of MelCTC isolation techniques,
from the use of single surface markers to novel methodologies that
rely on physical characteristics of MelCTCs. We also describe the
clinical signiﬁcance of current MelCTC studies, addressing the issues that in our informed opinion, hamper the progress of this
research ﬁeld.
Melanoma CTC enrichment techniques
Despite MelCTC heterogeneity [25,29,53], methods for their
capture and enrichment have relied predominantly on the
expression of one or two known cell surface markers (Fig. 1). For
example, immunomagnetic enrichment with magnetic beads
coupled to antibodies against known melanoma-speciﬁc antigens
has been used to enrich CTCs (positive selection). Alternate
methods that deplete white blood cells (WBCs) using beads targeting common leukocyte (CD45 or CD34) antigens (negative selection) are also widely used [28,34,44,52].
The CellSearch™ system (Veridex LCC) involves immunomagnetic capture of CTCs followed by cancer-speciﬁc marker
staining for CTC detection. This system is the only FDA-approved
CTC enumeration platform for breast, prostate and colorectal cancer, where EpCAM is used to capture CTCs followed by immunostaining with cytokeratin [2,10e12]. This adhesion molecule has
been described as important in tumor growth, EMT and metastasis
[37,38]; EpCAM is however, expressed exclusively in epithelial-

ATP binding cassette subfamily B member 5
American Joint Committee on Cancer
proto-oncogene B-Raf; v-Raf murine sarcoma viral oncogene homolog B
VE-Cadherin
LNGFR (low-afﬁnity nerve growth factor receptor)
p75 NTR (neurotrophin receptor)
cluster of differentiation 34
cluster of differentiation 45
cyclin-dependent kinase Inhibitor 2A
Cancer or CTC derived xenografts
copy number variation
circulating tumor cell
circulating tumor microemboli
droplet digital PCR
epithelial cell adhesion molecule
US Food and Drug Administration
glycoprotein 100; melanocyte protein PMEL
herringbone-chip
immunocytochemistry
isolation by size of epithelial tumor cells
proto-oncogene K-Ras; Kirsten rat sarcoma virus
Cytokeratin 18
Cytokeratin 8
mitogen-activated protein kinase
melanoma cell adhesion molecule
melanoma-associated chondroitin sulphate proteoglycan
proto-oncogene MDM2
melanoma circulating tumor cells
macrophage migration inhibitory factor
microphthalmia-associated transcription factor
melanoma antigen recognized by T cells 1
NOD scid gamma mice
paired box gene 3
programmed cell death protein 1
programmed Death-ligand 1
patient derived xenografs
progression free survival
phosphatase and tensin homolog
receptor activator of NF-kb
red blood cells
telomerase reverse transcriptase
white blood cells

derived neoplasms. A different CellSearch™ kit was therefore
developed for MelCTC isolation, which captures CTCs expressing
melanoma cell adhesion molecule (MCAM) from whole blood and
detects CTCs by immunostaining with MCSP/CSGP4/HMW-MAA
(melanoma-associated chondroitin sulphate proteoglycan).
Khoja and colleagues [28] used this melanoma speciﬁc CellSearch™ kit to detect CTCs in 101 metastatic melanoma patients,
and found 0e36 CTCs/7.5 mL of blood prior to treatment, with 40%
of patients having at least one CTC. Similarly, Rao and colleagues,
found 0 to 8042 CTCs/7.5 mL of blood in 23% of the patients
(n ¼ 44), with greater than 10 CTCs detected in only three patients
(4%) [44]. Given the low frequency of CTCs detected by targeting
only one marker for enrichment, other approaches increased the
number of antigens targeted in order to isolate a larger number of
MelCTCs.
Freeman and colleagues [21] found that using a combination of
MCSP, MCAM, ATP-binding cassette sub-family B member 5
(ABCB5), and cluster of differentiation 271 (CD271) targeting antibodies, captured MelCTCs in a signiﬁcantly higher proportion of
metastatic melanoma patients than did the use of MCSP or MCAM
alone. This ﬁnding demonstrated for the ﬁrst time the high diversity of MelCTCs and improved the sensitivity of bead-based CTC
enrichment compared with experiments that targeted single
markers. In this study, patients from all stages showed signiﬁcantly
higher numbers of CTCs than controls (n ¼ 15), detecting at least 1
CTC/mL of blood in 73.9% of patients (range: 0e2.5 CTCs/mL of
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Fig. 1. The most widely used circulating tumor cell enrichment, detection and molecular characterization technologies for melanoma and other cancers. NGS: next generation
sequencing. DEP: dielectrophoresis. ddPCR: droplet digital polymerase chain reaction. FISH: ﬂuorescence in situ hybridization. RT-PCR: real time polymerase chain reaction.

blood). However, despite this multimarker approach aimed at
improving the sensitivity of CTC capture, it still yielded low capture
efﬁciency (34%) in spiking experiments [21], suggesting that only a
few MelCTCs were being isolated.
To improve capture efﬁciency, the herringbone-chip (HB-chip)
technology has been developed. This device uses micro-vortices
generated by herringbone-shaped grooves to direct cells toward
channel walls coated with a combination of antibodies targeting
melanoma-speciﬁc antigens. The combination of HB-chip technology with a pool of 12 melanoma-speciﬁc antibodies for detection, allowed capture of CTCs (on average 8 CTCs/2.5 mL) by
immunostaining in 32/41 (79%) metastatic melanoma patients at
various stages of treatment [36]. These results underscore the need
for multiple markers to identify MelCTCs given their remarkable
heterogeneity. Nevertheless, these methods are not able to capture
all CTCs present within a patient, as those that do not express the
antigen of interest are missed.
To avoid capture bias, other studies have used negative selection
procedures which capture leukocytes with anti-CD45 antibody
coated beads followed by WBC depletion using magnetic separation. Systems such as EasySep™ or RosetteSep™ use this approach.
Fusi and colleagues, using the EasySep™ method and detecting
CTCs using gp100 and MLANA (melanoma antigen recognized by T
cells 1) by ﬂow cytometry, found 28/32 (87.5%) metastatic patients
had CTCs with a median of 53 CTCs/10 mL of blood [22]. Using
RosetteSep™, Girotti and colleagues successfully enriched CTCs and
injected them into NSG mice to generate CDX models [23]. While
the CTC quantities used to generate the models are unknown, it is
likely that relatively large numbers of cells were isolated for successful tumor uptake.
Although negative selection is advantageous for removing cells
that do not express the most common melanoma markers, the
purity of CTCs obtained in the enriched fraction is low, hampering
their quantiﬁcation and downstream analysis. In fact, a spiking
experiment comparing the recovery and purity of CD45 depletion
with positive enrichment, or a combination of both methods,
showed that the greatest recovery was found by using negative
selection (58% recovery rate). However, the greatest purity of the

CTC fraction was obtained by using the combination method
(background reduced from 3  107 to 1.5  103of WBCs) [34].
To further improve CTC capture, alternative techniques have
been developed recently that exploit the larger cell size of MelCTCs
compared to WBCs. Although it has been shown that MelCTCs can
have a diverse range of cell sizes [4,41], most of the CTCs are
thought to be larger (10e20 mm) than other blood components,
such as RBCs (6e8 mm), leukocytes (7e12 mm) or platelets
(2e3 mm). Taking advantage of this perceived difference in cell size,
the “enrichment by size of epithelial tumor cells” (ISET®) technique
was developed [58]. The ISET® system uses polycarbonate ﬁlters
with 8 mm diameter circular pores for CTC enrichment and detection of cells trapped in ﬁlters. De Giorgi and colleagues detected
CTCs in 29% and 62.5% of patients with primary invasive and
metastatic melanoma respectively, using qPCR to detect Tyrosinase
transcripts after ISET® ﬁltration; the limit of detection was 1 CTC/
mL of blood [14]. However, this approach also detected benign
circulating nevus cells [15], suggesting the inability of this assay to
distinguish between benign nevus cells and melanoma cells.
Alternatively, when using the same ISET enrichment technique,
with CTCs deﬁned by positive immunohistochemistry expression of
S100 and negative expression for CD45 or CD144 (leukocyte and
endothelial cell markers, respectively), 51/90 (57%) metastatic
melanoma patients had detectable CTCs (1e44 CTCs/mL of blood)
[29]. The low percentage of metastatic patients with high-burden
disease found with CTCs, shows the unsuitability of this method
for detecting all CTCs present in patients. This drove the combination of technologies that rely on physical properties of the
MelCTCs with those detecting expression of speciﬁc surface
markers.
The CTC-iChip separates cells based on size using deterministic
lateral displacement and inertial focusing followed by negative
depletion. Using this chip, CTCs from two metastatic melanoma
patients were successfully enriched and detected as positive by
staining for the melanoma antigen recognized by T cells 1 (MART-1/
MLANA) [41].
The OncoQuick® system is another size-based technique that
incorporates a ﬁlter for CTC separation in conjunction with density-
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based centrifugation [50]. Spiking experiments showed a 60%
recovery rate of 4, 20, 100 and 500 spiked SkMel28 cells when
assessed by qPCR ampliﬁcation of cytokeratin 8 (KRT8) and 18
(KRT18) RNA. The SkMel28 cell line strongly expresses these intermediate ﬁlament proteins and KRT18 expression has been previously identiﬁed as an adverse prognostic factor in melanoma [8].
For melanoma CTCs, when transcript levels of MLANA, MIF
(Macrophage Migration Inhibitory Factor), TYR, and MITF (Melanogenesis Associated Transcription Factor) were assessed by qPCR
after OncoQuick® enrichment, results showed that about 1/3 of
patients (mostly early-stage) expressed elevated levels of MIF and
MLANA transcripts, in comparison with healthy controls (p < 0.0001
and p < 0.001, respectively) [9]. The authors suggest that identiﬁcation of early-stage patients with CTCs may be used to delineate
those that would beneﬁt from a more aggressive therapy at an
earlier stage.
Previous studies have found circulating tumor microemboli
(CTM) or CTC clusters in the blood of melanoma patients, raising
the idea that cells enter the bloodstream via collective cell migration, allowing them to survive shear stress and anoikis forces
[29,42]. Recently, the Cluster-Chip was developed to speciﬁcally
isolate CTC clusters of two or more cells from 4 mL of blood,
independently of tumor-speciﬁc marker expression. This microchip
technology relies on the strength of the cluster union and on their
behavior when a ﬂow speed is applied through a set of triangular
pillars. Captured CTC clusters were identiﬁed and detected by immunostaining in 30% (~0.15 CTCs/mL) of 20 tested metastatic
melanoma patients. Interestingly, no correlation was found between the number of CTC clusters and the number of single CTCs
isolated (n ¼ 19) [53].
While these methods have proven the ability to capture CTCs,
clinical validation of their prognostic value in large clinical samples
is still needed.
Melanoma CTC detection methods
While the above techniques have been developed to improve
isolation of CTCs, optimization of detection methods is also
required. Detection of MelCTCs without a previous enrichment step
has been reported by Ruiz and colleagues [51], where the Epic
Sciences platform detected MelCTCs from whole blood, using a
panel of seven anti-MCSP monoclonal antibodies. MCSP is a cell
surface protein involved in melanoma proliferation, spreading and
migration of cells and it is overexpressed in more than 90% of
melanoma tumor tissue samples [6,13]. Using this marker for
detection, 1e250 CTCs were detected in 8 mL of blood (0.5e371.5
CTCs/mL of blood) from 22/40 metastatic melanoma patients (55%).
Interestingly, this method also enabled whole genome ampliﬁcation and copy number variation (CNV) analyses of single MelCTCs,
which revealed deletions of CDKN2A and PTEN, and ampliﬁcations
of melanoma related genes, TERT, BRAF, KRAS and MDM2 amongst
others [51].
Most commonly, once CTCs are enriched by the techniques
discussed above they are detected by methods that assess their
morphology and/or protein expression using immunocytochemistry (ICC) or ﬂow cytometry. In these techniques a cocktail of antibodies against cell surface or intracellular markers associated
with melanocyte biology or melanoma pathogenesis [21,25,30,55]
are used to recognize the cells. Alternately, molecular approaches
that detect RNA or DNA from enriched MelCTCs, by quantitative
real-time PCR (qRT-PCR) [4,39] or droplet digital PCR (ddPCR) [45],
respectively, have been used for CTC detection and characterization. A new and promising method based on the presence of
elevated telomerase activity commonly found in melanoma cells, is
being trialed for CTC detection [61].

Based on our previous identiﬁcation of heterogeneous MelCTCs
[21], we recently developed a ﬂow-cytometry multimarker
approach to detect and analyze CTCs for the presence of melanomaassociated markers, such as MCSP and MCAM, in combination with
melanoma stem cell markers, such as ABCB5, RANK (receptor
activator of NF-kb) and CD271 [25]. Using this approach we provided for the ﬁrst time, a detailed insight into the diversity of
MelCTCs within each patient, and showed that the prognostic
utility of MelCTCs may not rely on the total count of CTCs but on the
CTC subpopulations circulating within an individual. This study
indicated that a high number of MelCTCs express melanomainitiating or stem cell markers (ABCB5 and RANK) while only very
low numbers of CTCs express melanoma markers MCSP and MCAM
[25]. Importantly, the common expression of these melanomainitiating markers by MelCTCs did not correlate with the expression of these markers in patient-matched tumors, where a low
frequency of melanoma tumor cells positive for these markers was
observed. This ﬁnding provides evidence that most CTCs, at least in
melanoma, are derived from rare subpopulations of tumor cells
which may have the ability to seed new metastases, and not from
the bulk melanoma cells shaping the tumor [25].
Aya-Bonilla and colleagues [4] more recently interrogated for
the ﬁrst time, the enrichment of MelCTCs using spiral microﬂuidic
technology [59,60]. With this device, recovery rates of greater than
55% and a 2.5e3 log depletion of WBCs were observed in spiking
experiments using melanoma cell lines with different cell sizes
which represents an improvement to depletion rates similar to
those obtained by the CTC-iChip [41]. After microﬂuidic enrichment
of blood from 20 metastatic melanoma patients, MelCTCs were
identiﬁed by ﬂow cytometry, gene expression analysis and immunostaining, in 40%, 54% and 43% of cases, respectively. As found
previously [21,25,29], MelCTCs showed diversity in their marker
population with CTCs analyzed by ﬂow cytometry most commonly
expressing ABCB5 alone or in combination with RANK, a marker of
treatment resistance. Gene expression analysis of the CTC-enriched
fractions also detected transcripts of PAX3, alone or in combination
with ABCB5 expression in 6 out of 7 metastatic melanoma patients
positive for melanoma transcripts; transcripts of the melanocytic
gene, MLANA, were detected in the remaining patient. MLANA, PAX3
and ABCB5 are highly expressed in melanoma tumors and have
been described to play an important role in melanoma pathogenesis and resistance [17,20,43]. In this study, isolated CTCs were also
characterized by multimarker immunostaining for intracellular
melanocytic proteins gp100, S100 and MLANA (1e4 CTCs/8 mL of
blood), which indicated that MelCTCs are also diverse in cell size
(range: 13e21 mm) [4]. This study unmistakably conﬁrmed the
phenotypic and molecular heterogeneity of MelCTCs.
Although great advances have been made in MelCTC isolation
(Fig. 1; Table 2), their quantiﬁcation remains challenging given the
low numbers of CTCs identiﬁed even when a variety of multimarker
assays are used for their detection. This is presumably due to our
limited knowledge of the spectrum of diverse MelCTCs. Studies are
needed to investigate MelCTC phenotypes, their role in melanoma
biology and prognosis as well as their differential pharmacodynamic responses to treatment [31].
Are CTCs of clinical utility in melanoma?
Studies to date show CTCs are a suitable biomarker of disease
status. Furthermore, monitoring the levels of CTCs before and
during melanoma treatment has, in limited studies, been shown to
be informative with respect to prognosis and therapy response in
melanoma [25,28,31,36,46].
Using RT-PCR to detect transcripts in blood, Reid and colleagues
showed that in 230 patients, the presence of MLANA and ABCB5

G. Marsavela et al. / Cancer Letters 424 (2018) 1e8

5

Table 2
Assessment of MelCTC enrichment and detection techniques.
MelCTC Enrichment

Platform

Advantages

Positive
Immunomagnetic
Enrichment

CellSearch
HB-chip
Magnetic
beads
EasySep
RosetteSep
CTC-iChip
ISET
OncoQuick

(CellSearch FDA-approved method.) High speciﬁcity. Relies on prior knowledge of target cell surface markers.

[28,44]
[36]
[21]

Retrieves heterogeneous and viable MelCTCs.

[22]
[23]
[41]
[16,29]
[9,50]

Negative
Immunomagnetic
Enrichment
Technologies based on
Size/Density

Cluster Isolation
MelCTC Detection

Disadvantages

Fast processing time. Label-independent isolation.

Spiral
2.5e3 log WBC depletion. Enrichment of viable
Microﬂuidics MelCTCs.
Cluster-Chip Marker independent isolation. Potential study of
tumor-immune system interactions.
Advantages

Immunocytochemistry Individual cell analysis. Common protocols used.
Low cost.
Flow Cytometry
Automated quantiﬁcation. Provides multimarker
information.
qRT-PCR
Cost effective. High sensitivity.
ddPCR
High speciﬁcity. Cost effective.

Relies on no marker expression by CTCs and high expression by
leukocytes. High WBC background.
Low speciﬁcity. Not commercially available.
Low speciﬁcity. Limited studies.
High leukocytic background. Combination with other
enrichment methods needed.
Low speciﬁcity. Limited studies.

References

[4]

Lack of biological characterization and clinical signiﬁcance. Not [53]
commercially available.

Disadvantages

References

Time consuming. Low sensitivity. Biased CTC detection.

[4,51]

Marker expression-dependent; requires previous enrichment; limited number of [22,25,33]
markers.
Biased CTC detection. Unclear speciﬁcity. Not quantiﬁable.
[4,16,39]
Sensitivity compromised by WBC background. Analysis limited to prior knowledge [45]
of target mutation.

transcripts were associated with disease recurrence and the
expression of MCAM was signiﬁcantly more common in patients
with a poor treatment outcome [46]. Also, the presence of multiple
melanoma markers in patient blood signiﬁcantly correlated with
their AJCC stage [32], and the detection of more than one marker at
baseline and at any time during treatment administration was a
negative prognostic factor for disease-free survival (DFS) and for
overall survival (OS) [26].
Several studies using immunomagnetic enrichment have also
shown that the number of MelCTCs is higher in the blood of patients with advanced disease [21,36,62]. Moreover, the number of
CTCs was also shown to be associated with treatment failure and
shorter median OS when 2 CTCs per 7.5 mL are found during the
time that patients are receiving treatment [28,44]. By contrast, a
low CTC count at baseline (<2 CTCs) or a decrease in CTCs after
treatment initiation was associated with response to treatments
and longer progression free survival (PFS) rates [31].
Recently, using ﬂow cytometry to separate CTC subtypes, we
showed that the presence of CTCs was associated with disease stage
and PFS [25]. Interestingly, early-stage patients were generally
positive for a single marker compared to late-stage patients who
had larger numbers of CTCs expressing a variety of markers.
Additionally, patients with higher number of CTCs (>5 RANKþ cells)
in 4 mL of blood had signiﬁcantly lower PFS than those with fewer
or no CTCs (<5 RANKþ cells) [25]. Importantly, we demonstrated
that prognostic utility might be found not merely by using total
CTCs counts but by studying speciﬁc subpopulations of CTCs and
response to therapy. Patients (n ¼ 16) who relapsed after targeted
BRAF inhibitor therapy were most likely to exhibit greater numbers
of RANK CTC subtypes. Conversely, the presence of CTCs expressing
PD-L1 was associated with response to anti-PD1 blockade [27].
New experiments with patient-derived xenografts (PDX) are
providing new information that can inform treatment decisions for
each patient. Particularly where tumors are inaccessible, CTCderived xenografts (CDX) or in vitro growth of CTCs may provide
a powerful tool for drug efﬁcacy testing for each patient. Girotti and
colleagues [23] have been successful in generating CDXs in 6 out of
21 cases (28.6%) and showed that CDX models established from
advanced stage patients could aid in the prediction of patient responses to treatments [23]. While the isolation of only a few CTCs

capable of developing xenografts may underestimate the tumor
heterogeneity, these are excellent ﬁrst steps, addressing several of
the issues surrounding the clinical beneﬁt of CTC characterization,
including the fact that CTCs that develop xenografts are capable of
seeding metastases and therefore harbor signiﬁcant information
about the metastatic process. Additionally, further studies characterizing CTC subpopulations prior to or concurrently with injecting
them into mice will provide crucial information about CTC phenotypes that are most likely to develop CDXs.
Although CTCs quantiﬁcation shows great potential, the role of
MelCTCs in melanoma management is still under investigation. For
example, the continued presence or an increase of MelCTCs after
therapy initiation may suggest disease progression. Contrarily, a
decrease or a continued value of zero MelCTCs might suggest
response to treatment. Additionally, changes in CTC phenotype
after treatment initiation may be an early indicator of the emergence of resistance, leading to an early change of therapy. Although
these changes are difﬁcult to assess when low numbers of MelCTCs
are being isolated, these measurements could offer unique prognostic information. Furthermore, MelCTCs could be tested for molecular evolution of tumors prior to therapy, to identify markers of
intrinsic resistance; and during therapy, to identify the development of drug resistance to targeted therapies.
There is also a need to evaluate the ability of CTC analysis to
inform treatment decision in patients with AJCC stage III and
resected stage IV melanomas, as there are now more clinical trials
and FDA approved therapeutics for melanoma in stage III and stage
IV [3,35].
The lack of standardization and the variety of methodologies
used for their isolation has hampered the ability to implement the
analysis of MelCTCs into large clinical studies. Therefore, there is an
urgent need to standardized protocols for MelCTC enrichment,
detection, and quantiﬁcation across different laboratories.
What additional isolation steps are required to identify the full
spectrum of melanoma CTC subtypes and their prognostic potential?
Melanoma CTCs are rare and very heterogeneous. The comprehension of their aggressiveness and their application in clinical
settings is still limited by the capacity to successfully and routinely
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isolate viable heterogeneous CTCs from the majority of patients.
New platforms that enable effective and repetitive isolation of
MelCTCs should be unbiased, which means that CTCs should be
enriched and detected without relying on known expression of CTC
markers, rather, methods should be based on broader traits of CTCs,
such as physical properties (cell size, morphology, rigidity, nuclear/
cytoplasm ratio). In addition, isolation methods should be highly
efﬁcient in enriching the vast majority of CTCs present in the blood
at high purity (i.e. low WBC background). Moreover, methods
should allow isolation of viable and intact CTCs for “omic” characterization and, ultimately, the establishment of CTC-derived cell
cultures and xenografts (CDX). Furthermore, methods are required
that allow high throughput, are low cost and accessible in both
research and clinical environments.
Integration of genomic and transcriptomic data from bulk tumors [7] together with single-cell RNA-seq of melanoma tumors
[56] have reinforced the abundant diversity between and within
melanoma tumors. Thus CTCs derived from such tumors would
similarly carry heterogeneous features. However, the challenges in

isolating all CTCs have signiﬁcantly ﬂawed the interrogation of the
real genomic, transcriptomic and proteomic diversity of MelCTCs.
Finding a system able to capture and detect CTCs independently
of their cell marker characteristics is urgently needed in melanoma,
and a few studies trialing this isolation approach have been reported [4,14,29,41]. Advances remain hampered however by the
uncertain biology of these cells, and the lack of optimal technologies along with robust standardization and validation of these
technologies.
Although challenging, studying the gene expression and mutational landscape of single MelCTCs, their relationship with tumor
tissue cells and their connection with treatment response and
resistance, will signiﬁcantly increase the clinical value of this
biomarker. Improvements along these lines will dramatically
advance CTC use in the clinic. The recent implementation of devices
capable of isolating viable and label-free MelCTCs paves the way for
studies aimed at dissecting their real heterogeneity and the
mechanisms underlying their role in melanoma spreading. Moreover, the isolation and study of MelCTC clusters will provide an

Fig. 2. Potential applications and clinical beneﬁts of melanoma circulating tumor cells.
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insight into their role in melanoma progression and metastasis and
in the tumor-immune interactions.

[9]

Conclusion
[10]

In conclusion, a variety of isolation methods have been developed in order to study the prognostic and predictive applications of
CTCs in melanoma. Moving forward, the implementation of optimal
isolation techniques allowing phenotypic, genomic and transcriptomic approaches is critical in order to unveil the diversity of
MelCTCs and provide new insights into their clinical opportunities
(Fig. 2). The latest studies suggest that examining CTC subpopulations instead of quantifying CTCs, could signiﬁcantly impact
their clinical utility. However, the variety of subpopulations needs
to be identiﬁed and clinical trials assessing the biomarker utility of
these subpopulations needs to be undertaken to draw meaningful
conclusions. Also, critical factors such as the time of blood collection (i.e., different time points), site of collection of blood sample
[24], sample handling, transport and storage must not be overlooked and remains to be standardized. Although promising,
MelCTC isolation and study still holds technological limitations that
ought to be considered by MelCTC specialists worldwide to maximize their potential applications in clinical practice.
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